These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 25256433)

  • 41. The efficacy and safety of novel oral anticoagulants for the preventive treatment in atrial fibrillation patients: a systematic review and meta-analysis.
    Liu GJ; Wang YF; Chen PY; Chang W; Tu ML; Chang LY; Cheng P; Luo J
    Drug Deliv; 2014 Sep; 21(6):436-52. PubMed ID: 24400656
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Thoughts about anticoagulation in older patients].
    Gil Gregorio P
    Med Clin (Barc); 2016 Aug; 147(4):151-3. PubMed ID: 27068787
    [No Abstract]   [Full Text] [Related]  

  • 43. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.
    Heidbuchel H; Verhamme P; Alings M; Antz M; Diener HC; Hacke W; Oldgren J; Sinnaeve P; Camm AJ; Kirchhof P
    Europace; 2015 Oct; 17(10):1467-507. PubMed ID: 26324838
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Effective anticoagulation also in advanced age].
    Zimmermann W
    MMW Fortschr Med; 2015 Feb; 157(3):72. PubMed ID: 25743684
    [No Abstract]   [Full Text] [Related]  

  • 45. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.
    Fox KA; Piccini JP; Wojdyla D; Becker RC; Halperin JL; Nessel CC; Paolini JF; Hankey GJ; Mahaffey KW; Patel MR; Singer DE; Califf RM
    Eur Heart J; 2011 Oct; 32(19):2387-94. PubMed ID: 21873708
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chronic anticoagulation in chronic kidney disease.
    Ball T; Wheelan K; McCullough PA
    J Am Coll Cardiol; 2014 Dec; 64(23):2483-5. PubMed ID: 25500232
    [No Abstract]   [Full Text] [Related]  

  • 47. ACP Journal Club. Review: Novel oral anticoagulants reduce stroke more than ASA in nonvalvular atrial fibrillation.
    Neumann I; Brignardello-Petersen R; Guyatt G
    Ann Intern Med; 2014 Feb; 160(4):JC3. PubMed ID: 24534937
    [No Abstract]   [Full Text] [Related]  

  • 48. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial.
    Hu PT; Lopes RD; Stevens SR; Wallentin L; Thomas L; Alexander JH; Hanna M; Lewis BS; Verheugt FW; Granger CB; Jones WS
    J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28096100
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs.
    Verheugt FW; Granger CB
    Lancet; 2015 Jul; 386(9990):303-10. PubMed ID: 25777666
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
    Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
    Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Stroke and systemic embolism prevention in patients with atrial fibrillation in Belgium: comparative cost effectiveness of new oral anticoagulants and warfarin.
    Kongnakorn T; Lanitis T; Annemans L; Thijs V; Goethals M; Marbaix S; Wautrecht JC
    Clin Drug Investig; 2015 Feb; 35(2):109-19. PubMed ID: 25511639
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial.
    Lopes RD; Al-Khatib SM; Wallentin L; Yang H; Ansell J; Bahit MC; De Caterina R; Dorian P; Easton JD; Erol C; Ezekowitz JA; Gersh BJ; Granger CB; Hohnloser SH; Horowitz J; Hylek EM; McMurray JJ; Mohan P; Vinereanu D; Alexander JH
    Lancet; 2012 Nov; 380(9855):1749-58. PubMed ID: 23036896
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Role of Nonvitamin K Antagonist Oral Anticoagulants (NOACs) in Stroke Prevention in Patients with Atrial Fibrillation.
    Kuznetsov S; Barcelona R; Josephson RA; Mohan SK
    Curr Neurol Neurosci Rep; 2016 May; 16(5):47. PubMed ID: 27023335
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality, and Bleeding: A Nationwide Cohort Study.
    Nielsen PB; Larsen TB; Skjøth F; Gorst-Rasmussen A; Rasmussen LH; Lip GY
    Circulation; 2015 Aug; 132(6):517-25. PubMed ID: 26059010
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dabigatran etexilate (Pradaxa) for the treatment of atrial fibrillation.
    Belavic JM
    Nurse Pract; 2011 Sep; 36(9):6-7. PubMed ID: 21857210
    [No Abstract]   [Full Text] [Related]  

  • 56. Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
    Senoo K; Lip GY
    Semin Thromb Hemost; 2015 Mar; 41(2):146-53. PubMed ID: 25682085
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
    Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
    Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Influence of chronic kidney disease on warfarin therapy for atrial fibrillation.
    Shah R; Roberts KM; Ramanathan KB
    JAMA; 2014 Jun; 311(24):2542. PubMed ID: 25058090
    [No Abstract]   [Full Text] [Related]  

  • 59. Influence of chronic kidney disease on warfarin therapy for atrial fibrillation.
    Vaduganathan M; Greene SJ
    JAMA; 2014 Jun; 311(24):2541-2. PubMed ID: 25058089
    [No Abstract]   [Full Text] [Related]  

  • 60. Hypertension, chronic kidney disease, atrial fibrillation and the newer anticoagulants: Prof Brian Rayner comments.
    Hardy G
    Cardiovasc J Afr; 2012 Jul; 23(6):348-9. PubMed ID: 23091826
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.